328 related articles for article (PubMed ID: 27671305)
1. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
Ahmed MF; Magdy N
Anticancer Agents Med Chem; 2017; 17(6):832-838. PubMed ID: 27671305
[TBL] [Abstract][Full Text] [Related]
2. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
[TBL] [Abstract][Full Text] [Related]
4. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Zhang Y; Chen L; Xu H; Li X; Zhao L; Wang W; Li B; Zhang X
Eur J Med Chem; 2018 Mar; 147():77-89. PubMed ID: 29421573
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
6. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Mowafy S; Farag NA; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.
El-Azab AS; Al-Omar MA; Abdel-Aziz AA; Abdel-Aziz NI; el-Sayed MA; Aleisa AM; Sayed-Ahmed MM; Abdel-Hamide SG
Eur J Med Chem; 2010 Sep; 45(9):4188-98. PubMed ID: 20599299
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity.
Li HQ; Li DD; Lu X; Xu YY; Zhu HL
Bioorg Med Chem; 2012 Jan; 20(1):317-23. PubMed ID: 22112541
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
Abouzid K; Shouman S
Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
[TBL] [Abstract][Full Text] [Related]
12. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W
Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of Some Dibromoquinazoline-sulphonamide Hybrids and some Schiff´s Base Analogs for their Cytotoxic Activity.
Ahmed MF; El-Haggar R
Anticancer Agents Med Chem; 2017 Nov; 17(11):1563-1569. PubMed ID: 28356022
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
El Ella DA; Saleh KA; Hassan M; Hamdy N; El-Araby ME; Abouzid KA
Arzneimittelforschung; 2012 Aug; 62(8):360-6. PubMed ID: 22723174
[TBL] [Abstract][Full Text] [Related]
18. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W
Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives.
Wang L; Li P; Li B; Wang Y; Li J; Song L
Molecules; 2017 Sep; 22(10):. PubMed ID: 28956845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]